OCTEU brings together over 1,000 leaders from the pharmaceutical and biotechnological sectors to share success stories and discuss solutions to accelerate clinical trial timelines.

‍

In addition to sponsoring the event, our co-founder, Gabriel Maeztu, will be part of the panel 'Exploring the Transition of Innovation and Technological Advances in Clinical Trials'. During this symposium, Gabriel will share insights on the impact of artificial intelligence and machine learning in the industry. Furthermore, he will explain how IOMED is leading the way in implementing these technologies to optimize the collection of clinical data and streamline patient recruitment for clinical trials.

‍

He will share the panel with María Reyes Boceta-Muñoz, Clinical Operations Manager of GSK Spain; Laura Jiménez Robledo, Director of Clinical Projects and Innovation at Novo Nordisk; Upinder Grewal, Strategic Director of Exploration and Development at Bayer; and Mats Sundgren, Industrial Scientific Director of the European Institute for Innovation through Health Data.

‍

"We are excited to participate and sponsor OCTEU 24 and to collaborate in the field of clinical trials, to drive progress and provide solid answers to the challenges we face today," expresses Gabriel Maeztu.

‍

This event is a unique opportunity for biotechnological and pharmaceutical companies, as well as trial sponsors, medical device manufacturers, and solution providers, to collaborate, connect, and work securely towards success in their clinical trials.

‍